Comparison of the Biological Effects of Long-Term Exposure of Human Bronchial Epithelial Cells to Total Particulate Matter from 3R4F Cigarette Smoke or Aerosol from the Candidate Modified Risk Tobacco Product (cMRTP) THS2.2
Poster Jan 24, 2017
M. van der Toorn, D. Marescotti, S. Johne, K. Baumer, D. Bornand, R. Dulize, C. Merg, A. Sewer, P. Leroy, N. Ivanov, M. Peitsch, J. Hoeng, and K. Luettich
Chronic cigarette smoke exposure leads to airway epithelial changes underlying lung tumorigenesis, although the molecular events are not fully elucidated. We mimicked chronic exposure in smokers’ airways by continuously exposing BEAS-2B cells to TPM from 3R4F cigarette smoke or aerosol of the Tobacco Heating System 2.2 (THS2.2), a cMRTP, for 12 weeks.
Several endpoints including proliferation, DNA damage, oxidative stress, epithelial-mesenchymal transition (EMT) and wound repair were assessed monthly. Soft-agar assays were performed after 12 weeks, and resulting clones were tested for invasion. Cells were also collected regularly for systems toxicological analysis. Increased oxidative stress and DNA damage were noticeable within the first 2 weeks of 3R4F TPM treatment, but subsided thereafter, indicating adaptation.
Four-week 3R4F TPM treatment resulted in crisis and EMT. By week 8, cells regained E-cadherin expression, suggesting EMT was reversible. Increased MMP levels and decreased wound repair were noted in 3R4F TPM-treated cells at week 12.
However, these changes were not observed following prolonged treatment of BEAS-2B cells with the same or a 5-fold higher concentration of THS2.2 TPM, while a 20-fold higher concentration also increased oxidative burden, DNA damage and caused reversible EMT. In addition, anchorage-independent growth was observed in 3R4F and THS2.2 TPM-treated BEAS-2B cells. 3R4F TPM-derived clones were invasive, while THS2.2 TPM clones were not. Systems toxicological analysis indicated an overall smaller biological impact of THS2.2 compared with 3R4F TPM, confirming a differential effect of the two TPMs. Further analysis by DNA sequencing and in vitro xenograft assay is currently underway.
Severe Combined Immunodeficiency (SCID) caused by thymic aplasia due to a mutation in TBX1Poster
We report one of the first cases of TBX1 haploinsufficiency causing complete thymic aplasia and SCID.READ MORE
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell ImmunotherapiesPoster
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.READ MORE
Exploiting Polypharmacology in Precision Oncology: Identification of Differential Kinase Off-targets Among Clinical PARP InhibitorsPoster
Can we use computational methods to identify previously unknown off-targets of PARP inhibitors that can explain their observed differences?READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018